fda compounding semaglutide crackdown news today Drugmakers battle pharmacies over compounded Ozempic and Zepbound : Shots Feds warn telehealth companies about

Working closely with healthcare providers allows for personalized treatment plans that address individual concerns while maintaining medical safety

Major weight loss, pain relief seen with Eli Lilly's next-gen drug in late-stage trial Retatrutide reduced knee pain by up to 75.8% in late-stage trial A new weight-loss drug that Eli Lilly is testing is helping patients in a late-stage trial lose an average of 28.7% of their body weight and offered "substantial" relief from osteoarthritis pain

Weight loss plateaus are a normal part of the process reflecting metabolic adaptation, not medication failure

Its ability to promote weight loss can also alleviate obesity-related stress on the kidneys, improving overall kidney function

Maintaining a healthy diet and exercise routine is essential for keeping the weight off

Retatrutide produces greater blood pressure reduction than semaglutide